PFE
NYSE · Pharmaceuticals
Pfizer Inc.
$25.08
-0.13 (-0.52%)
PFE News30 articles
Pfizer Stock Hovers Near Recent Lows After CFO Departure Sparks Growth Concerns
Pfizer shares remain near last week's selloff levels after CFO Dave Denton's planned departure raised concerns about growth and the company's obesity drug ambitions.
Pfizer Shares Slip as CFO Departure Rattles Investors; 2026 Outlook Intact
Pfizer shares fell 2.7% to $25.21 after CFO Dave Denton said he will leave in August, reigniting investor concerns over succession and obesity-drug competition.
Pfizer CFO Departure Casts Shadow on 2026 Growth Plans
Pfizer shares dropped 2.7% as CFO Dave Denton's departure raises fresh questions about the 2026 forecast and obesity drug pipeline.
Pfizer CFO Departure Raises Growth Strategy Questions, Stock Slips 3%
Pfizer shares slid 3.2% after announcing CFO Dave Denton's departure, intensifying investor scrutiny of the company's 2026 guidance and obesity drug strategy.
Pfizer Shares Edge Up as Rigel Completes Veppanu Licensing Deal
Pfizer shares edged up after Rigel completed a Veppanu licensing deal with Arvinas, providing a $35 million payment to Pfizer.
Pfizer Holds Steady at $26.21, 6.6% Yield Attracts Amid Drug Pricing and Pipeline Risks
Pfizer shares ended the session nearly unchanged at $26.21, with a 6.6% dividend yield drawing income-focused investors even as drug pricing pressures and patent cliff risks cloud the outlook.
Pfizer Edges Higher at $26.21 Amid Dividend Draw and Pipeline Optimism
Pfizer closed Friday at $26.21, up 0.15%, outperforming its sector despite German pricing pressures and a European legal setback. Focus remains on its 6.56% dividend yield and pipeline progress in obesity and oncology.
Pfizer Shares Edge Higher After RBC Upgrade
Pfizer shares edged up Friday after RBC Capital upgraded the stock to Sector Perform, citing a more balanced risk-reward. Investors now focus on upcoming 2026 oncology trial data.
Pfizer Stock Rises on RBC Upgrade Despite German Drug-Pricing Threat
Pfizer shares rose 2.7% to $26.28 after RBC Capital upgraded the stock to Sector Perform, citing improved risk-reward. Meanwhile, a Reuters report flags German drug-pricing policy risks that could affect investments.
Wall Street Mixed as AI Rally Faces Key Inflation Test
U.S. stocks traded mixed Tuesday as the Dow and S&P 500 posted modest gains while the Nasdaq dipped, with market focus on upcoming inflation data and AI sector strength.
Pfizer Stock Dips Despite FDA Nod for Hemophilia Drug Hympavzi
Pfizer shares fell premarket despite FDA approval for hemophilia drug Hympavzi, as investors focus on slower obesity drug progress and pipeline challenges.
J&J Shares Rise Amid Market Turmoil; Pipeline and Dividend in Focus
Johnson & Johnson shares rose 2.02% on Friday, outperforming the S&P 500, as a Los Angeles jury found the company not negligent in a talc lawsuit.
Abivax shares drop despite positive Phase 3 results for ulcerative colitis drug
Abivax shares plunged 33.7% after hours despite obefazimod achieving clinical remission in over 50% of patients in a Phase 3 trial. The company plans to submit an FDA application in late Q4 2026.
Pfizer's Cancer Pipeline Takes Center Stage After ASCO Data Dump
Pfizer enters Monday's trading with a wealth of new cancer drug data from ASCO and a $10.5B China partnership, positioning the stock for a potential re-rating.
AbbVie Stock Gains on Positive Pipeline Updates Ahead of Holiday
AbbVie closed Friday at $215.70, up 0.56%, after receiving a positive EU panel recommendation for MAVIRET in acute hepatitis C and releasing new oncology data ahead of ASCO.
Pfizer Faces Investor Scrutiny After Weekly Decline Amid Pipeline Concerns
Pfizer shares dropped 1.63% on Friday to $25.33, lagging the S&P 500. Despite a 5% revenue increase and reaffirmed 2026 guidance, investor caution persists over pipeline risks and competitive pressure from Eli Lilly.
J&J Stock Dips on Friday but Posts Weekly Gain; Key Catalysts Ahead
J&J shares fell 1.77% Friday amid a broad selloff but still gained 2.4% for the week. Next week, investors watch pipeline data and a medtech launch.
Tonix Pharma Surges on Promising Lyme Antibody Data; Phase 2 Trial Eyed for 2027
Tonix Pharmaceuticals shares rose after new Phase 1 modeling data for its Lyme antibody TNX-4800 showed six-month protection with two doses. A Phase 2 trial is targeted for 2027.
Pfizer Ramps Up India Expansion, Faces Investor Skepticism
Pfizer is expanding into India with cancer, obesity, and vaccine investments, but investors remain cautious. Q1 revenue rose 5% to $14.5 billion, though generic competition looms.
Pfizer's Recovery Play: Can New Drugs Offset Patent Cliff?
Pfizer stock gains on Q1 beat and steady outlook, but investors weigh patent cliff risks against new oncology and GLP-1 drug prospects.
Pfizer's COVID Patent Woes Persist as Investors Eye Growth Beyond Vaccines
A Delaware federal judge dismissed Acuitas Therapeutics' attempt to clear Pfizer's Comirnaty vaccine from GSK patent claims, leaving the patent dispute unresolved. Pfizer shares fell 1.42% to $25.68.
Novavax Shares Surge on Pfizer Deal, Vaccine Strategy Shift
Novavax shares surged 13% Friday after Q1 revenue of $139.5 million beat estimates, fueled by a $30 million Pfizer licensing deal for Matrix-M adjuvant.
Novavax Surges on Pfizer Deal, Q1 Revenue Beat Despite Weak Vaccine Sales
Novavax reported Q1 revenue of $139.5M, beating estimates, driven by $30M from Pfizer's Matrix-M license. Shares rose further as licensing income offset weak COVID vaccine sales.
Novavax Surges on Pfizer Deal, Beats Q1 Revenue Forecasts
Novavax topped Q1 revenue estimates at $139.5M, driven by a $30M Pfizer payment, offsetting weak COVID vaccine sales. Shares rose 15.6%.
Pfizer Q1 Beats Estimates, Patent Cliff Concerns Linger
Pfizer reported Q1 adjusted EPS of $0.75 on $14.45B revenue, beating estimates. Growth in Eliquis and Padcev offset COVID declines, but patent cliff remains a key concern.
Futures Edge Higher as Oil Retreats, JOLTS Data in Focus
U.S. stock futures edged higher Tuesday as oil prices pulled back, with the Nasdaq 100 leading gains ahead of JOLTS data and earnings from AMD, Pfizer, and KKR.
Pfizer and Arvinas Secure First PROTAC Approval in Breast Cancer
The FDA approved Veppanu, a first-of-its-kind PROTAC pill from Pfizer and Arvinas, for advanced breast cancer with ESR1 mutations. The decision precedes Pfizer's Q1 earnings report.
Pfizer Gains on FDA Priority Review for Padcev as Pipeline Pivots Post-COVID
Pfizer shares advanced after the FDA granted priority review for its Padcev bladder cancer therapy, setting an August decision. Investors await Q1 results to gauge progress in oncology and obesity drugs against fading COVID sales.
Major Investors Reduce Pfizer Holdings Amid Growth Transition
Three institutional investors trimmed their Pfizer positions by a combined 740,174 shares in the fourth quarter, filings show, as the pharmaceutical giant navigates its post-pandemic transition.
Pfizer Shares Reach New Peak Amid Divergent Views on Future Growth
Pfizer shares surged to a 52-week high of $28.30, driven by robust quarterly results and promising oncology data. Analysts remain divided on whether the stock's rally is sustainable given looming growth challenges.